Katz, Guy http://orcid.org/0000-0001-5370-4907
Ogdie, Alexis http://orcid.org/0000-0002-4639-0775
Baker, Joshua F. http://orcid.org/0000-0003-0799-7563
George, Michael D. http://orcid.org/0000-0002-0398-2308
Article History
Received: 6 September 2021
Revised: 27 November 2021
Accepted: 28 December 2021
First Online: 27 January 2022
Declarations
:
: As this study utilized a de-identified dataset, the study was deemed exempt by the University of Pennsylvania Institutional Review Board.
: The manuscript does not contain clinical studies or patient data.
: Not applicable.
: Not applicable.
: Dr. Guy Katz has no disclosures. Dr. Alexis Ogdie has served as a consultant for AbbVie, Amgen, BMS, Celgene, Corrona, Gilead, Global Health Living Foundation, Janssen, Lilly, Novartis, Pfizer, and UCB (less than 10,000 each in past 12 months) and has received grants from Novartis and Pfizer to Penn and from Amgen to Forward (grants more than 10,000). Dr. Joshua Baker has received consulting fees from Bristol-Myers Squibb and Gilead. Dr. Michael George is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases 1K23AR073931-01.